Telomir Pharmaceuticals, INC 10-Q quarterly reports

Telomir Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing development of Telomir-Zn, significant net losses, and substantial doubt regarding its ability to continue as a going concern.

Telomir Pharmaceuticals reports reduced operating costs and net loss in Q1 2026, following the completion of its merger with TELI and securing future funding commitments.

Telomir Pharmaceuticals reported reduced net losses and increased cash reserves, driven by recent equity financings, while announcing a binding LOI to acquire worldwide rights for its lead candidate, Telomir-1.

Telomir Pharmaceuticals reported a significant net loss in Q2 2025, driven by increased stock-based compensation, while advancing multiple preclinical programs and securing new equity financing.

Telomir Pharmaceuticals reports a net loss for Q1 2025 while highlighting preclinical study results for Telomir-1 in various age-related and other conditions.

Telomir Pharmaceuticals reported a net loss of $13.6 million for the nine months ended September 30, 2024, and expressed substantial doubt about its ability to continue as a going concern.

Telomir Pharmaceuticals reported its second quarter 2024 financial results, marked by increased operating expenses and a significant net loss, alongside major changes in its executive leadership and board composition.

Telomir Pharmaceuticals reported a net loss of $6.3 million for the first quarter of 2024, driven by increased research and development and general administrative expenses, despite a successful IPO.